References
- Zimetbaum P. Antiarrhythmic Drug Therapy for Atrial Fibrillation. Circulation. 2012;125(2):381–9.
- Bray JJH, Warraich M, Whitfield MG, et al. Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation. Cochrane Database of Systematic Reviews. 2023;(3).
- Saljic A, Heijman J, Dobrev D. Recent Advances in Antiarrhythmic Drug Therapy. Drugs. 2023;83(13):1147–60.
- Fatima A, Rasool S, Devi S, et al. Exploring the Cardiovascular Benefits of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Expanding Horizons Beyond Diabetes Management. Cureus. 2023;15(9).
- Duan HY, Barajas-Martinez H, Antzelevitch C, Hu D. The potential anti-arrhythmic effect of SGLT2 inhibitors. Cardiovascular Diabetology. 2024;23(1):1–17.
- Chen S, Coronel R, Hollmann MW, Weber NC, Zuurbier CJ. Direct cardiac effects of SGLT2 inhibitors. Cardiovasc Diabetol. 2022;21(1):1–13.
- Fedele D, Casuso Alvarez M, Maida A, et al. Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2025;00:1–10.
- Pandey AK, Okaj I, Kaur H, et al. Sodium-glucose co-transporter inhibitors and atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2021;10(17):22222.
- Jaiswal V, Ang SP, Kumar D et al. Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias: A Meta-Analysis of 38 Randomized Controlled Trials. JACC: Advances. 2025;4(3).
- Curtain JP, Docherty KF, Jhund PS, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J. 2021 ;42(36):3727–38.
- Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413–24.
- McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995–2008.
- Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451–61.
- Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644–57.
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
- Filippatos G, Farmakis D, Butler J, et al. Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation. Eur J Heart Fail. 2023;25(7):970–7.
- Fujiki S, Iijima K, Nakagawa Y, et al. Effect of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable cardioverter-defibrillator: the EMPA-ICD trial. Cardiovasc Diabetol. 2024;23(1).
- Zelniker TA, Bonaca MP, Furtado RHM, et al. Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial. Circulation. 2020;141(15):1227–34.
- Lin M, Zhang S, Zhang L, et al. Redefining outcomes of ventricular arrhythmia for SGLT2 inhibitor medication in heart failure patients: a meta-analysis of randomized controlled trials. Syst Rev. 2025;14(1).
- Butt JH, Docherty KF, Jhund PS, et al. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. Eur J Heart Fail. 2022;24(3):513–25.
- Cesaro A, Gragnano F, Paolisso P, et al. In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study. Front Cardiovasc Med. 2022;9.
- Ling AWC, Chan CC, Chen SW, et al. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Cardiovasc Diabetol. 2020 ;19(1):188.
- Engstrom A, Wintzell V, Melbye M, et al. Sodium–Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study. Diabetes Care. 2023;46(2):351–60.
- Chan YH, Chao TF, Chen SW, et al. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study. Cardiovasc Diabetol. 2022;21(1).
- Noh HJ, Cha SJ, Kim CH, Choi SW, Lee CH, Hwang JK. Efficacy of dapagliflozin in improving arrhythmia-related outcomes after ablation for atrial fibrillation: a retrospective single-center study. Clinical Research in Cardiology. 2024;113(6):924–32.
- Zhao Z, Jiang C, He L, et al. Impact of Sodium-Glucose Cotransporter 2 Inhibitor on Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With Diabetes: A Propensity-Score Matching Study and Meta-Analysis. J Am Heart Assoc. 2023;12(24):31269.
- Minguito Carazo C, Rodriguez Manero M, Garcia Seara J, et al. Impact of SLGT2 inhibitors treatment initiation on the reduction of atrial and ventricular arrhythmias in patients with implanted cardiac defibrillator. Eur Heart J. 2024;45(Supplement_1).
- Hu Z, Ju F, Du L, Abbott GW. Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death. Cardiovasc Diabetol. 2021;20(1).
- Abu-Qaoud MR, Kumar A, Tarun T, et al. Impact of SGLT2 Inhibitors on AF Recurrence After Catheter Ablation in Patients With Type 2 Diabetes. Clinical Electrophysiology. 2023;9(10):2109–18.
- Kishima H, Mine T, Fukuhara E, Kitagaki R, Asakura M, Ishihara M. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes After Catheter Ablation for Atrial Fibrillation. JACC Clin Electrophysiol. 2022;8(11):1393–404.
- Benedikt M, Oulhaj A, Rohrer U, et al. Ertugliflozin to Reduce Arrhythmic Burden in Patients with ICDs/CRT-Ds. NEJM evidence. 2024;3(10).
- Quagliariello V, De Laurentiis M, Rea D, et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol. 2021;20(1).
- Ma HX, Wu K, Dong FH, Cai BK, Wu D, Lu HY. Effects of Empagliflozin and Dapagliflozin in alleviating cardiac fibrosis through SIRT6-mediated oxidative stress reduction. Sci Rep. 2024;14(1).
- Chen X, Yang Q, Bai W, et al. Dapagliflozin Attenuates Myocardial Fibrosis by Inhibiting the TGF-β1/Smad Signaling Pathway in a Normoglycemic Rabbit Model of Chronic Heart Failure. Front Pharmacol. 2022;13.
- Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 2008;1(1):62–73.
- Shao Q, Meng L, Lee S, et al. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats. Cardiovasc Diabetol. 2019;18(1):1–14.
- Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2021;77(3):243–55.
- Santosgallego CG, Requena-Ibanez JA, Vargas A, et al. The SGLT2 Inhibitor Empagliflozin Ameliorates Left Atrial Dilatation in Non-Diabetic Patients With Heart Failure With Reduced Ejection Fraction: A Secondary Analysis of the EMPATROPISM Trial. Circulation. 2020;142(Suppl_3).
- Thiele K, Rau M, Grebe J, et al. Empagliflozin Improves Left Atrial Strain in Patients with Type 2 Diabetes: Data from a Randomized, Placebo-Controlled Study. Circ Cardiovasc Imaging. 2023;16(4):E015176.
- Basalay M V., Korsak A, He Z, Gourine A V., Davidson SM, Yellon DM. SGLT2 Inhibition Induces Cardioprotection by Increasing Parasympathetic Activity. Circ Res. 2024;136:229–31.
- Shimizu W, Kubota Y, Hoshika Y, et al. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: The EMBODY trial. Cardiovasc Diabetol. 2020 Sep 25; 19(1):1–12.
- Butler J, Jones WS, Udell JA, et al. Empagliflozin after Acute Myocardial Infarction. New England Journal of Medicine. 2024;390(16):1455–66.
- James S, Erlinge D, Storey RF, et al. Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. NEJM Evidence. 2023;3(2).
- Valdivia CR, Chu WW, Pu J, et al. Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. J Mol Cell Cardiol. 2005;38(3):475–83.
- Philippaert K, Kalyaanamoorthy S, Fatehi M, et al. Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin. Circulation. 2021;143(22):2188–204.
- Hegyi B, Mira Hernandez J, Shen EY, Habibi NR, Bossuyt J, Bers DM. Empagliflozin Reverses Late Na+Current Enhancement and Cardiomyocyte Proarrhythmia in a Translational Murine Model of Heart Failure with Preserved Ejection Fraction. Circulation. 2022;145(13):1029–31.
- Mustroph J, Wagemann O, Lücht CM, et al. Empagliflozin reduces ca/calmodulin-dependent kinase ii activity in isolated ventricular cardiomyocytes. ESC Heart Fail. 2018;5(4):642–8.
- Gager GM, von Lewinski D, Sourij H, Jilma B, et al. Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure. Biomedicine & Pharmacotherapy. 2021;143:112169.
- Mustroph J, Baier MJ, Pabel S, et al. Empagliflozin Inhibits Cardiac Late Sodium Current by Ca/Calmodulin-Dependent Kinase II. Circulation. 2022;146(16):1259–61.
- Müller ME, Petersenn F, Hackbarth J, et al. Electrophysiological Effects of the Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitor Dapagliflozin on Human Cardiac Potassium Channels. Int J Mol Sci. 2024;25(11):5701.